menu
    • menu
    [{"orgOrder":0,"company":"Ensoma","sponsor":"National Marrow Donor Program","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"MGTA-145","moa":"CXCR-2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Ensoma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ensoma \/ National Marrow Donor Program","highestDevelopmentStatusID":"8","companyTruncated":"Ensoma \/ National Marrow Donor Program"},{"orgOrder":0,"company":"Ensoma","sponsor":"Bluebird Bio","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"MGTA-145","moa":"CXCR-2 receptor","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Ensoma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ensoma \/ Bluebird Bio","highestDevelopmentStatusID":"8","companyTruncated":"Ensoma \/ Bluebird Bio"},{"orgOrder":0,"company":"Ensoma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"MGTA-145","moa":"CXCR-2 receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ensoma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ensoma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ensoma \/ Undisclosed"},{"orgOrder":0,"company":"Ensoma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"MGTA-145","moa":"CXCR-2 receptor","graph1":"Nephrology","graph2":"Phase I","graph3":"Ensoma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ensoma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ensoma \/ Undisclosed"},{"orgOrder":0,"company":"Ensoma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"EN-374","moa":"CYBB","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ensoma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ensoma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ensoma \/ Undisclosed"},{"orgOrder":0,"company":"Ensoma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"EN-374","moa":"CYBB","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ensoma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ensoma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ensoma \/ Undisclosed"},{"orgOrder":0,"company":"Ensoma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"EN-374","moa":"CYBB","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ensoma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ensoma \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Ensoma \/ Undisclosed"},{"orgOrder":0,"company":"Ensoma","sponsor":"Ensoma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ensoma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ensoma \/ Ensoma","highestDevelopmentStatusID":"3","companyTruncated":"Ensoma \/ Ensoma"},{"orgOrder":0,"company":"Ensoma","sponsor":"5Am Ventures","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Preclinical","graph3":"Ensoma","amount2":0.070000000000000007,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Rare Diseases","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Ensoma \/ 5Am Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Ensoma \/ 5Am Ventures"},{"orgOrder":0,"company":"Ensoma","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Ensoma","amount2":0.14000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Ensoma \/ Kite Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Ensoma \/ Kite Pharma"},{"orgOrder":0,"company":"Ensoma","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2025","type":"Financing","leadProduct":"EN-374","moa":"CYBB","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Ensoma","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"Infusion","sponsorNew":"Ensoma \/ Gilead Sciences","highestDevelopmentStatusID":"7","companyTruncated":"Ensoma \/ Gilead Sciences"}]

    Find Clinical Drug Pipeline Developments & Deals by Ensoma

    Menu

    Ensoma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Ensoma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Ensoma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EN-374

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Gilead Sciences

                            Deal Size : $53.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Ensoma Announces $53 Million Financing to Support Key Clinical Milestones for EN-374

                            Details : The financing will support Ensoma’s recently initiated Phase 1/2 clinical trial for EN-374 in X-linked chronic granulomatous disease (X-CGD).

                            Product Name : EN-374

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            September 22, 2025

                            Lead Product(s) : EN-374

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Gilead Sciences

                            Deal Size : $53.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Ensoma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Ensoma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EN-374

                            Therapeutic Area : Genetic Disease

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ensoma gets FDA IND Clearance for First In Vivo HSC Gene Insertion Therapy

                            Details : EN-374 is a first-in-class in vivo HSC-directed therapy for X-CGD, which is caused by mutations in the CYBB gene of the NAPDH oxidase complex in neutrophils.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 12, 2025

                            Lead Product(s) : EN-374

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ensoma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Ensoma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EN-374

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of EN-374 Gene Therapy in Participants With X-Linked Chronic Granulomatous Disease

                            Details : EN-374 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Granulomatous Disease, Chronic.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            March 14, 2025

                            Lead Product(s) : EN-374

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Ensoma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Ensoma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : EN-374

                            Therapeutic Area : Genetic Disease

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ensoma's EN-374 Gets Rare Pediatric, Orphan Drug Status for Granulomatous Disease

                            Details : EN-374 is a CD46/CYBB modulator, gene therapy candidate, which is currently being evaluated for the treatment of X-linked chronic granulomatous disease (X-CGD).

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 13, 2025

                            Lead Product(s) : EN-374

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ensoma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Ensoma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Kite Pharma

                            Deal Size : $135.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Ensoma Closes Series B Extension, Bringing Total Round to $135 Million

                            Details : The fundings will advance the development of Ensoma’s Engenious™ in vivo engineered cell therapy platform and pipeline of genomic medicines for immuno-oncology, genetic disease and other therapeutic applications.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 16, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Kite Pharma

                            Deal Size : $135.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Ensoma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Ensoma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Recipient : Twelve Bio

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Ensoma Announces Closing of Twelve Bio Acquisition

                            Details : The company’s Engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 09, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Recipient : Twelve Bio

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Ensoma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Ensoma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MGTA-145

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Sponsor : Bluebird Bio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of MGTA-145 and Plerixafor in Patients With Sickle Cell Disease

                            Details : MGTA-145 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Anemia, Sickle Cell.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 06, 2022

                            Lead Product(s) : MGTA-145

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Sponsor : Bluebird Bio

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Ensoma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Ensoma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MGTA-145

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : National Marrow Donor Program

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies

                            Details : MGTA-145 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            February 21, 2021

                            Lead Product(s) : MGTA-145

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : National Marrow Donor Program

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Ensoma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Ensoma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Preclinical

                            Sponsor : 5Am Ventures

                            Deal Size : $70.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Ensoma Launches to Pioneer Next-Generation In Vivo Approach to Deliver First “Off-the-shelf” Genomic Medic...

                            Details : Company’s Engenious™ vectors Delivered without Stem Cell Collection or Myeloablative Conditioning in Outpatient and Low-Resource Settings, Enabling Access Worldwide.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            February 11, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Preclinical

                            Sponsor : 5Am Ventures

                            Deal Size : $70.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Ensoma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed

                            Ensoma

                            U.S.A arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MGTA-145

                            Therapeutic Area : Nephrology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal I...

                            Details : MGTA-145 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Renal Insufficiency.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            November 06, 2019

                            Lead Product(s) : MGTA-145

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth